A long-term comparison of proquazone and naproxen in the treatment of osteoarthritis of the hip.
The efficacy and tolerance of 900 mg/day proquazone were compared with those of 500 mg/day naproxen in a three-month trial with 40 patients suffering from osteoarthritis of the hip. Proquazone was found to be more effective than naproxen in providing relief of symptoms and improving the patient's condition. The side effects of proquazone were exclusively gastrointestinal but occurred more frequently than with naproxen. With one exception, none of the symptoms were serious enough to require suspension of therapy. These results suggest that the action of proquazone provides a good balance between clinical efficacy and tolerance.
D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006621:Hip Joint; D006801:Humans; D008297:Male; D008875:Middle Aged; D009288:Naproxen / Q000009:adverse effects / Q000627:therapeutic use*; D010003:Osteoarthritis / Q000188:drug therapy*; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D011799:Quinazolines; D009288:Naproxen